ARA-290 (cibinetide) is a small peptide designed from the structure of erythropoietin (EPO). It acts on a tissue-repair receptor without stimulating red blood cell production. It has been in phase 2 trials and is not FDA approved.
Also known as: Cibinetide.
Powder vials are usually labeled 10 mg.
Water and syringe-unit charts by vial size: 10 mg
Here is the math for a 10 mg vial mixed with 2 mL of bacteriostatic water, drawing 4 mg with a U-100 insulin syringe (1 mL = 100 units).
10 mg ÷ 2 mL = 5 mg/mL4 mg ÷ 5 mg/mL = 0.8 mL0.8 mL × 100 = 80 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 2 mg | 0.4 mL | 40 units |
| 4 mg | 0.8 mL | 80 units |
| 8 mg | 1.6 mL | 160 units (over 1 mL) |
Adding more water doesn't change how much ARA-290 is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 1 mL | 10 mg/mL | 0.4 mL | 40 units |
| 2 mL | 5 mg/mL | 0.8 mL | 80 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
In a phase 2 trial in type 2 diabetes with painful neuropathy (Brines 2015), people injected 4 mg under the skin daily for 28 days or placebo; no safety issues were identified. In a phase 2b trial in 64 people with sarcoidosis-related small nerve fiber loss (Culver 2017), daily doses of 1, 4 or 8 mg for 28 days were compared with placebo; the 4 mg group had the clearest increase in corneal nerve fibers.
We could not open a primary human source with a half-life for ARA-290, so we do not list one here.